Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Alirocumab, a monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9), has been shown to reduce low-density lipoprotein (LDL) cholesterol levels in patients who are receiving statin therapy. Larger and longer-term studies are needed to establish safety and efficacy. METHODS: We conducted a randomized trial involving 2341 patients at high risk for cardiovascular events who had LDL cholesterol levels of 70 mg per deciliter (1.8 mmol per liter) or more and were receiving treatment with statins at the maximum tolerated dose (the highest dose associated with an acceptable side-effect profile), with or without other lipid-lowering therapy. Patients were randomly assigned in a 2:1 ratio to receive alirocumab (150 mg) or placebo as a 1-ml subcutaneous injection every 2 weeks for 78 weeks. The primary efficacy end point was the percentage change in calculated LDL cholesterol level from baseline to week 24. RESULTS: At week 24, the difference between the alirocumab and placebo groups in the mean percentage change from baseline in calculated LDL cholesterol level was -62 percentage points (P<0.001); the treatment effect remained consistent over a period of 78 weeks. The alirocumab group, as compared with the placebo group, had higher rates of injection-site reactions (5.9% vs. 4.2%), myalgia (5.4% vs. 2.9%), neurocognitive events (1.2% vs. 0.5%), and ophthalmologic events (2.9% vs. 1.9%). In a post hoc analysis, the rate of major adverse cardiovascular events (death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization) was lower with alirocumab than with placebo (1.7% vs. 3.3%; hazard ratio, 0.52; 95% confidence interval, 0.31 to 0.90; nominal P=0.02). CONCLUSIONS: Over a period of 78 weeks, alirocumab, when added to statin therapy at the maximum tolerated dose, significantly reduced LDL cholesterol levels. In a post hoc analysis, there was evidence of a reduction in the rate of cardiovascular events with alirocumab. (Funded by Sanofi and Regeneron Pharmaceuticals; ODYSSEY LONG TERM ClinicalTrials.gov number, NCT01507831.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The efficacy at reducing LDL-C is in the range of 50-70%, independent of the presence of a background therapy (statins, ezetimibe, etc.); preliminary data from phase 3 trials suggest a reduction of CV events in line with the LDL-C reduction achieved.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [115]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the initial trials of these drugs, the incidence of neurocognitive adverse events (including delirium, cognitive and attentional disturbances, dementia, thought and perceptual disturbances, and psychiatric disorders) was very low (<1%) but slightly higher albeit non-significantly in the treated groups compared with placebo (0.9% vs. 0.3% for evolocumab) (81) (1.2% vs. 0.5% for alirocumab) (82).”
From PCSK9 and the nervous system: a no-brainer? (2023) · cites this paper as [81]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“alirocumab, a PCSK9 monoclonal antibody in clinical use (Robinson et al., 2015)”
From γ-secretase inhibition lowers plasma triglyceride-rich lipoproteins by stabilizing the LDL receptor (2018) · cites this paper as Robinson et al., 2015
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Data from the GLAGOV, ODYSSEY COMBO I and ODYSSEY LONG TERM trials show greater efficacy of PCSK9 inhibitors in patients with prior CVD (or myocardial infarction) in terms of LDL-C and percent atheroma volume [86–88].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [88]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The beneficial effect of ezetimibe is also supported by genetic studies of mutations in NPC1L1; naturally occurring mutations that inactivate the protein were found to be associated with reduced plasma LDL-C and reduced risk for CAD [55,269,270].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [270]
Experimental — accuracy not yet measured
11 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Self-citationCholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Self-citationNiacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Effects of dalcetrapib in patients with a recent acute coronary syndrome
Schwartz, G. G., Olsson, A. G., Abt, M., Ballantyne, C. M., Barter, P. J., Brumm, J., Chaitman, B. R., Holme, I. M., Kallend, D., Leiter, L. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206797 · Cited by 2,022
Effects of extended-release niacin with laropiprant in high-risk patients
The HPS2-THRIVE Collaborative Group (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300955 · Cited by 1,668
Cited by
Items 101–200 of 1,019
Hepatic cholesterol transport and its role in non-alcoholic fatty liver disease and atherosclerosis
Li, H., Yu, X.-H., Ou, X., Ouyang, X.-P., & Tang, C.-K. (2021) · Progress in Lipid Research · doi:10.1016/j.plipres.2021.101109 · Cited by 227
Human Genetics and the Causal Role of Lipoprotein(a) for Various Diseases
Kronenberg, F. (2016) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-016-6648-3 · Cited by 230
“levels and reduced the incidence of cardiovascular events [87, 88].”
BackgroundFrom target discovery to clinical drug development with human genetics
Trajanoska, K., Bhérer, C., Taliun, D., Zhou, S., Richards, J. B., & Mooser, V. (2023) · Nature · doi:10.1038/s41586-023-06388-8 · Cited by 220
Leander, K., Mälarstig, A., van’t Hooft, F. M., Hyde, C., Hellénius, M.-L., Troutt, J. S., Konrad, R. J., Öhrvik, J., Hamsten, A., & de Faire, U. (2016) · Circulation · doi:10.1161/circulationaha.115.018531 · Cited by 221
2018 Guidelines for the management of dyslipidemia
Rhee, E.-J., Kim, H. C., Kim, J. H., Lee, E. Y., Kim, B. J., Kim, E. M., Song, Y., Lim, J. H., Kim, H. J., Choi, S., et al. (2019) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2019.188 · Cited by 213
Ginsberg, H. N., Rader, D. J., Raal, F. J., Guyton, J. R., Baccara-Dinet, M. T., Lorenzato, C., Pordy, R., & Stroes, E. (2016) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-016-6685-y · Cited by 214
“In a previous study with 2341 randomized patients treated for 78 weeks, alirocumab indicated a reduction of cardiovascular events in a post-hoc analysis [25]; however, additional data are required to confirm this observation.”
BackgroundMethodSelf-citationKaratasakis, A., Danek, B. A., Karacsonyi, J., Rangan, B. V., Roesle, M. K., Knickelbine, T., Miedema, M. D., Khalili, H., Ahmad, Z., Abdullah, S., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.006910 · Cited by 215
Metabolomics and Proteomics in Type 2 Diabetes
Chen, Z.-Z., & Gerszten, R. E. (2020) · Circulation Research · doi:10.1161/circresaha.120.315898 · Cited by 204
Xiao, C., Dash, S., Morgantini, C., Hegele, R. A., & Lewis, G. F. (2016) · Diabetes · doi:10.2337/db16-0046 · Cited by 212
Giugliano, R. P., Wiviott, S. D., Blazing, M. A., De Ferrari, G. M., Park, J.-G., Murphy, S. A., White, J. A., Tershakovec, A. M., Cannon, C. P., & Braunwald, E. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2017.0083 · Cited by 205
Efficacy and safety of evolocumab in chronic kidney disease in the FOURIER trial
Charytan, D. M., Sabatine, M. S., Pedersen, T. R., Im, K., Park, J.-G., Pineda, A. L., Wasserman, S. M., Deedwania, P., Olsson, A. G., Sever, P. S., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.03.513 · Cited by 210
Palasubramaniam, J., Wang, X., & Peter, K. (2019) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.119.312578 · Cited by 192
Guedeney, P., Giustino, G., Sorrentino, S., Claessen, B. E., Camaj, A., Kalkman, D. N., Vogel, B., Sartori, S., De Rosa, S., Baber, U., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehz430 · Cited by 208
Kamstrup, P. R., & Nordestgaard, B. G. (2016) · JACC: Heart Failure · doi:10.1016/j.jchf.2015.08.006 · Cited by 206
PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease
Schmidt, A. F., Pearce, L. S., Wilkins, J. T., Overington, J. P., Hingorani, A. D., & Casas, J. P. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011748.pub2 · Cited by 205
Familial hypercholesterolemia treatments: Guidelines and new therapies
Raal, F. J., Hovingh, G. K., & Catapano, A. L. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.06.859 · Cited by 194
Self-citationMoriarty, P. M., Parhofer, K. G., Babirak, S. P., Cornier, M.-A., Duell, P. B., Hohenstein, B., Leebmann, J., Ramlow, W., Schettler, V., Simha, V., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw388 · Cited by 197
Bernelot Moens, S. J., Neele, A. E., Kroon, J., van der Valk, F. M., Van den Bossche, J., Hoeksema, M. A., Hoogeveen, R. M., Schnitzler, J. G., Baccara-Dinet, M. T., Manvelian, G., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx002 · Cited by 191
Self-citationAre PCSK9 Inhibitors the Next Breakthrough in the Cardiovascular Field?
Giugliano, R. P., & Sabatine, M. S. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.05.001 · Cited by 199
Safety of Very Low Low-Density Lipoprotein Cholesterol Levels With Alirocumab
Robinson, J. G., Rosenson, R. S., Farnier, M., Chaudhari, U., Sasiela, W. J., Merlet, L., Miller, K., & Kastelein, J. J. P. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.11.037 · Cited by 197
Self-citationStatin non-adherence and residual cardiovascular risk: There is need for substantial improvement
Banach, M., Stulc, T., Dent, R., & Toth, P. P. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.09.075 · Cited by 197
2018 Guidelines for the Management of Dyslipidemia in Korea
Rhee, E.-J., Kim, H. C., Kim, J. H., Lee, E. Y., Kim, B. J., Kim, E. M., Song, Y., Lim, J. H., Kim, H. J., Choi, S., et al. (2019) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2019.8.2.78 · Cited by 192
Evaluating drug targets through human loss-of-function genetic variation
Minikel, E. V., Karczewski, K. J., Martin, H. C., Cummings, B. B., Whiffin, N., Rhodes, D., Alföldi, J., Trembath, R. C., van Heel, D. A., Daly, M. J., et al. (2020) · Nature · doi:10.1038/s41586-020-2267-z · Cited by 187
Drug delivery systems for CRISPR-based genome editors
Madigan, V., Zhang, F., & Dahlman, J. E. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00762-x · Cited by 172
“The described biological mechanism is supported by genetic evidence that PCSK9 affects lipid levels 231 and clinical evidence that inhibition of PCSK9 using an FDA-approved antibody 232,233 or siRNA 234 treatment reduces LDL levels.”
BackgroundFarnier, M., Jones, P., Severance, R., Averna, M., Steinhagen-Thiessen, E., Colhoun, H. M., Du, Y., Hanotin, C., & Donahue, S. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.11.010 · Cited by 189
Self-citationTriglycerides and Triglyceride-Rich Lipoproteins in the Causal Pathway of Cardiovascular Disease
Budoff, M. (2016) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2016.04.004 · Cited by 184
Updates on Acute Coronary Syndrome: A Review
Eisen, A., Giugliano, R. P., & Braunwald, E. (2016) · JAMA Cardiology · doi:10.1001/jamacardio.2016.2049 · Cited by 185
Wang, N., Fulcher, J., Abeysuriya, N., Park, L., Kumar, S., Di Tanna, G. L., Wilcox, I., Keech, A., Rodgers, A., & Lal, S. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30388-2 · Cited by 187
Vallejo-Vaz, A. J., Fayyad, R., Boekholdt, S. M., Hovingh, G. K., Kastelein, J. J., Melamed, S., Barter, P., Waters, D. D., & Ray, K. K. (2018) · Circulation · doi:10.1161/circulationaha.117.032318 · Cited by 187
Self-citationTargeting proprotein convertase subtilisin/kexin type 9 (PCSK9): From bench to bedside
Bao, X., Liang, Y., Chang, H., Cai, T., Feng, B., Gordon, K., Zhu, Y., Shi, H., He, Y., & Xie, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01690-3 · Cited by 187
Kessler, T., Vilne, B., & Schunkert, H. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201506174 · Cited by 173
“Circ Cardiovasc Genet 8:”
Benn, M., Nordestgaard, B. G., Frikke-Schmidt, R., & Tybjærg-Hansen, A. (2017) · BMJ · doi:10.1136/bmj.j1648 · Cited by 178
Lipids and Cerebrovascular Disease: Research and Practice
Yaghi, S., & Elkind, M. S. V. (2015) · Stroke · doi:10.1161/strokeaha.115.011164 · Cited by 176
Sabatine, M. S., Giugliano, R. P., Keech, A., Honarpour, N., Wang, H., Liu, T., Wasserman, S. M., Scott, R., Sever, P. S., & Pedersen, T. R. (2016) · American Heart Journal · doi:10.1016/j.ahj.2015.11.015 · Cited by 176
Borow, K. M., Nelson, J. R., & Mason, R. P. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.07.035 · Cited by 175
Efficacy and Safety of Alirocumab in Adults With Homozygous Familial Hypercholesterolemia
Blom, D. J., Harada-Shiba, M., Rubba, P., Gaudet, D., Kastelein, J. J. P., Charng, M.-J., Pordy, R., Donahue, S., Ali, S., Dong, Y., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.05.027 · Cited by 166
Self-citationColhoun, H. M., Ginsberg, H. N., Robinson, J. G., Leiter, L. A., Müller-Wieland, D., Henry, R. R., Cariou, B., Baccara-Dinet, M. T., Pordy, R., Merlet, L., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw292 · Cited by 172
Self-citationBergeron, N., Phan, B. A. P., Ding, Y., Fong, A., & Krauss, R. M. (2015) · Circulation · doi:10.1161/circulationaha.115.016080 · Cited by 171
Jawi, M., Frohlich, J. J., & Chan, S. (2020) · Journal of Lipids · doi:10.1155/2020/3491764 · Cited by 207
Myotoxicity of statins: Mechanism of action
du Souich, P., Roederer, G., & Dufour, R. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.029 · Cited by 161
2017 Taiwan lipid guidelines for high risk patients
Li, Y.-H., Ueng, K.-C., Jeng, J.-S., Charng, M.-J., Lin, T.-H., Chien, K.-L., Wang, C.-Y., Chao, T.-H., Liu, P.-Y., Su, C.-H., et al. (2017) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2016.11.013 · Cited by 157
Landmesser, U., John Chapman, M., Farnier, M., Gencer, B., Gielen, S., Hovingh, G. K., Lüscher, T. F., Sinning, D., Tokgözoğlu, L., Wiklund, O., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw480 · Cited by 162
Self-citationRecent Advances in Treatment of Coronary Artery Disease: Role of Science and Technology
Kandaswamy, E., & Zuo, L. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020424 · Cited by 180
“Since high LDL levels are linked to CAD, the use of Alirocumab reduced adverse cardiovascular events by 15–48% [127,131,132].”
BackgroundF. Piepoli, M. (2017) · International Journal of Behavioral Medicine · doi:10.1007/s12529-016-9583-6 · Cited by 162
RNA Therapeutics in Cardiovascular Disease
Lucas, T., Bonauer, A., & Dimmeler, S. (2018) · Circulation Research · doi:10.1161/circresaha.117.311311 · Cited by 173
Ference, B. A., Cannon, C. P., Landmesser, U., Lüscher, T. F., Catapano, A. L., & Ray, K. K. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx450 · Cited by 161
Prognostic value of PCSK9 levels in patients with acute coronary syndromes
Gencer, B., Montecucco, F., Nanchen, D., Carbone, F., Klingenberg, R., Vuilleumier, N., Aghlmandi, S., Heg, D., Räber, L., Auer, R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv637 · Cited by 158
“inhibitor trials demonstrated up to 50% reduction in major adverse cardiovascular (CV) events in high-risk patients after acute coronary syndromes (ACS) or familial hypercholesterolaemia.(7,8) We have shown clinical familial hypercholesterolaemia to be highly prevalent among patients with ACS (20%), and LDL cholestero…”
BackgroundCardiovascular risk and dyslipidemia among persons living with HIV: a review
Maggi, P., Biagio, A. D., Rusconi, S., Cicalini, S., D’Abbraccio, M., d’Ettorre, G., Martinelli, C. V., Nunnari, G., Sighinolfi, L., Spagnuolo, V., et al. (2017) · BMC Infectious Diseases · doi:10.1186/s12879-017-2626-z · Cited by 168
Cheng, H., Zhong, W., Wang, L., Zhang, Q. H., Ma, X., Wang, Y., Wang, S., He, C., Wei, Q., & Fu, C. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.114198 · Cited by 174
Surprises from genetic analyses of lipid risk factors for atherosclerosis
Musunuru, K., & Kathiresan, S. (2016) · Circulation Research · doi:10.1161/circresaha.115.306398 · Cited by 159
Bonicalzi, M.-È., Haince, J.-F., Droit, A., & Poirier, G. G. (2005) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-004-4505-1 · Cited by 171
Statins and PCSK9 inhibitors: A new lipid-lowering therapy
Gallego-Colon, E., Daum, A., & Yosefy, C. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173114 · Cited by 156
Interaction between platelets and endothelium: from pathophysiology to new therapeutic options
Hamilos, M. I., Petousis, S., & PARTHENAKIS, F. I. (2018) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt.2018.07.01 · Cited by 155
“Monoclonal antibodies acting as PCSK-9 inhibitors reduce impressively LDL-C when added to maximally tolerated statin therapy, improving patient’s clinical outcome (91,92).”
BackgroundNanchen, D., Gencer, B., Auer, R., Räber, L., Stefanini, G. G., Klingenberg, R., Schmied, C. M., Cornuz, J., Müller, O., Vogt, P., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv289 · Cited by 153
“The Simon Broome algorithm identified 5.4% (95% CI 4.8–6.1%, n ¼ 259) patients with possible FH.”
BackgroundInfluentialA cholesterol-lowering VLP vaccine that targets PCSK9
Crossey, E., Amar, M. J., Sampson, M. L., Peabody, J., Schiller, J. T., Chackerian, B., & Remaley, A. T. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.09.044 · Cited by 162
Fonarow, G. C., KEECH, A. C., Pedersen, T. R., Giugliano, R. P., Sever, P., Lindgren, P., van Hout, B., Villa, G., Qian, Y., Somaratne, R. M., et al. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2017.2762 · Cited by 159
Steg, P. G., Szarek, M. J., Bhatt, D. L., Bittner, V., Brégeault, M.-F., Dalby, A. J., Díaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.038840 · Cited by 160
“Monoclonal antibodies targeting proprotein convertase subtilisin-kexin type 9 (PCSK9) produce substantial and sustained reductions in low-density lipoprotein cholesterol (LDL-C), alone or when added to statin therapy.(1-4) In the FOURIER(5) and SPIRE-2(6) trials, treatment with the PCSK9 antibodies evolocumab or bococ…”
Self-citationType 2 Diabetes Variants Disrupt Function of SLC16A11 through Two Distinct Mechanisms
Rusu, V., Hoch, E., Mercader, J. M., Tenen, D. E., Gymrek, M., Hartigan, C. R., DeRan, M., von Grotthuss, M., Fontanillas, P., Spooner, A., et al. (2017) · Cell · doi:10.1016/j.cell.2017.06.011 · Cited by 152
“…insightshavebeendeveloped fordiseases ranging from monogenic disorders, such as cystic fibrosis, to common diseases, such as hypercholesterolemia, coronary artery disease, and T2D (Cohen et al., 2006; Nauck, 2014; Robinson et al., 2015; Sabatine et al., 2015; Wainwright et al., 2015).”
Background2016 European Guidelines on cardiovascular disease prevention in clinical practice
Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., Cooney, M. T., Corrà, U., Cosyns, B., Deaton, C., et al. (2016) · Kardiologia Polska · doi:10.5603/kp.2016.0120 · Cited by 177
Khan, S. U., Yedlapati, S. H., Lone, A. N., Hao, Q., Guyatt, G., Delvaux, N., Bekkering, G. E. (., Vandvik, P. O., Riaz, I. B., Li, S., et al. (2022) · BMJ · doi:10.1136/bmj-2021-069116 · Cited by 151
Targeting PCSK9 to tackle cardiovascular disease
Hummelgaard, S., Vilstrup, J. P., Gustafsen, C., Glerup, S., & Weyer, K. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108480 · Cited by 150
Norata, G. D., Tavori, H., Pirillo, A., Fazio, S., & Catapano, A. L. (2016) · Cardiovascular Research · doi:10.1093/cvr/cvw194 · Cited by 154
Jyotsna, F., Ahmed, A., Kumar, K., Kaur, P., Chaudhary, M. H., Kumar, S., Khan, E. A., Khanam, B., Shah, S. U., Varrassi, G., et al. (2023) · Cureus · doi:10.7759/cureus.43882 · Cited by 192
“This particular process leads to the depletion of cellular NADPH and contributes to oxidative stress by compromising antioxidant defense mechanisms [16].”
BackgroundTriple‐Targeting Delivery of CRISPR/Cas9 To Reduce the Risk of Cardiovascular Diseases
Zhang, L., Wang, L., Xie, Y., Wang, P., Deng, S., Qin, A., Zhang, J., Yu, X., Zheng, W., & Jiang, X. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201903618 · Cited by 147
Lindholm, D. P., Lindbäck, J., Armstrong, P. W., Budaj, A., Cannon, C. P., Granger, C. B., Hagström, E., Held, C., Köenig, W., Östlund, O., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.06.030 · Cited by 149
Cholesteryl Ester Transfer Protein Inhibition for Preventing Cardiovascular Events
Armitage, J., Holmes, M. V., & Preiss, D. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.10.072 · Cited by 140
Du, Z., & Qin, Y. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12010363 · Cited by 140
“Two clinically available anti-PCSK9 monoclonal antibodies, evolocumab and alirocumab, can offer greater reductions (50–60%) than those feasible through the application of NPC1L1 inhibitors [11].”
BackgroundYamauchi, T., Masuda, T., Canver, M. C., Seiler, M., Semba, Y., Shboul, M., Al‐Raqad, M., Maeda, M., Schoonenberg, V. A. C., Cole, M. A., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.01.012 · Cited by 150
“…of low-frequency coding-sequence variants that alter the risk of coronary artery disease and the successful translation of that approach to drug development (Abifadel et al., 2003; Myocardial Infarction Genetics and CARDIoGRAM Exome Consortia Investigators et al., 2016; Sabatine et al., 2015).”
BackgroundCatapano, A. L., Pirillo, A., & Norata, G. D. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13805 · Cited by 148
“While it could appear surprising that PCSK9 inhibitors, which decrease LDL-C levels up to 60% (Robinson et al., 2015; Sabatine et al., 2015), do not affect CRP levels, also in the placebo arm (statins and/or ezetimibe treated patients) of almost all clinical trials, no significant changes in CRP plasma levels were obs…”
BackgroundLeiter, L. A., Cariou, B., Müller‐Wieland, D., Colhoun, H. M., Prato, S. D., Tinahones, F. J., Ray, K. K., Bujas‐Bobanovic, M., Domenger, C., Mandel, J., et al. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13114 · Cited by 141
Langsted, A., Nordestgaard, B. G., Benn, M., Tybjærg-Hansen, A., & Kamstrup, P. R. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1206 · Cited by 136
“However, PCSK9 inhibitor treatment has also been shown to lower lipoprotein(a) (15, 16).”
BackgroundNavarese, E. P., Kołodziejczak, M. M., Winter, M., Alimohammadi, A., Lang, I. M., Buffon, A., Lip, G. Y. H., & Siller-Matula, J. M. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.10.084 · Cited by 140
Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor
Kasichayanula, S., Grover, A., Emery, M. G., Gibbs, M. A., Somaratne, R., Wasserman, S. M., & Gibbs, J. P. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0620-7 · Cited by 135
Protective alleles and modifier variants in human health and disease
Harper, A. R., Nayee, S., & Topol, E. J. (2015) · Nature Reviews Genetics · doi:10.1038/nrg4017 · Cited by 141
Lipoprotein apheresis to treat elevated lipoprotein (a)
Waldmann, E., & Parhofer, K. G. (2016) · Journal of Lipid Research · doi:10.1194/jlr.r056549 · Cited by 137
Vergallo, R., Porto, I., D’Amario, D., Annibali, G., Galli, M., Benenati, S., Bendandi, F., Migliaro, S., Fracassi, F., Aurigemma, C., et al. (2019) · JAMA Cardiology · doi:10.1001/jamacardio.2019.0275 · Cited by 139
Duell, P. B., Santos, R. D., Kirwan, B., Witztum, J. L., Tsimikas, S., & Kastelein, J. J. P. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2016.04.013 · Cited by 134
Self-citationEffect of Alirocumab on Lipoprotein(a) Over ≥1.5 Years (from the Phase 3 ODYSSEY Program)
Gaudet, D., Watts, G. F., Robinson, J. G., Minini, P., Sasiela, W. J., Edelberg, J. M., Louie, M. J., & Raal, F. J. (2016) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2016.09.010 · Cited by 139
“010 individual phase 3 studies, alirocumab reduced Lp(a) by an average of 25% to 30% from baseline to week 24 in patients with HeFH and in non-FH patients.(4,8) The aim of the present analysis was to evaluate the maintenance of the Lp(a)lowering effect with alirocumab over 24 to 104 weeks in a pooled analysis of 10 ph…”
BackgroundSelf-citationProof That Lower Is Better — LDL Cholesterol and IMPROVE-IT
Jarcho, J. A., & Keaney, J. F. (2015) · New England Journal of Medicine · doi:10.1056/nejme1507041 · Cited by 131
Lintner, N. G., McClure, K. F., Petersen, D., Londregan, A. T., Piotrowski, D. W., Wei, L., Xiao, J., Bolt, M., Loria, P. M., Maguire, B., et al. (2017) · PLOS Biology · doi:10.1371/journal.pbio.2001882 · Cited by 128
Coronary Atherosclerosis: Pathophysiologic Basis for Diagnosis and Management
Boudoulas, K. D., Triposkiadis, F. K., Geleris, P., & Boudoulas, H. K. (2016) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2016.04.003 · Cited by 152
Vulnerable Plaque, Characteristics, Detection, and Potential Therapies
Hafiane, A. (2019) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd6030026 · Cited by 144
Meschia, J. F., & Brott, T. G. (2017) · European Journal of Neurology · doi:10.1111/ene.13409 · Cited by 144
“When added to statin therapy, levels of low-density lipoprotein lower than 70 mg/dl can be achieved rapidly and sustainably with these agents [23].”
Roth, E. M., Moriarty, P. M., Bergeron, J., Langslet, G., Manvelian, G. Z., Zhao, J. M., Baccara‐Dinet, M. T., & Rader, D. J. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.043 · Cited by 129
Self-citationDetermining When to Add Nonstatin Therapy
Robinson, J. G., Huijgen, R., Ray, K. K., Persons, J. E., Kastelein, J. J. P., & Pencina, M. J. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.09.928 · Cited by 137
Self-citationHypercholesterolaemia and vascular dementia
Appleton, J. P., Scutt, P., Sprigg, N., & Bath, P. M. (2017) · Clinical Science · doi:10.1042/cs20160382 · Cited by 149
Management of diabetic dyslipidemia: An update
Jialal, I., & Singh, G. (2019) · World Journal of Diabetes · doi:10.4239/wjd.v10.i5.280 · Cited by 120
Lipid lowering therapy and circulating PCSK9 concentration
Nozue, T. (2017) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv17012 · Cited by 127
Ray, K. K., Ginsberg, H. N., Davidson, M. H., Pordy, R., Bessac, L., Minini, P., Eckel, R. H., & Cannon, C. P. (2016) · Circulation · doi:10.1161/circulationaha.116.024604 · Cited by 127
Self-citationThe evolution of domain arrangements in proteins and interaction networks
Bornberg‐Bauer, E., Beaussart, F., Kummerfeld, S., Teichmann, S. A., & Weiner, J. M. (2005) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-004-4416-1 · Cited by 142
Mendelian Randomization Study of PCSK9 and HMG-CoA Reductase Inhibition and Cognitive Function
Rosoff, D. B., Bell, A. S., Jung, J., Wagner, J., Mavromatis, L. A., & Lohoff, F. W. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.05.041 · Cited by 126
An oral antisense oligonucleotide for PCSK9 inhibition
Gennemark, P., Walter, K., Clemmensen, N., Rekić, D., Nilsson, C. A. M., Knöchel, J., Hölttä, M., Wernevik, L., Rosengren, B., Kakol-Palm, D., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abe9117 · Cited by 120
PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease
Schmidt, A. F., Carter, J.-P. L., Pearce, L. S., Wilkins, J. T., Overington, J. P., Hingorani, A. D., & Casas, J. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011748.pub3 · Cited by 123
2023 China Guidelines for Lipid Management
Li, J., Zhao, S., Zhao, D., Lü, G., Peng, D., Liu, J., Chen, Z., Guo, Y., Wu, N., Yan, S.-K., et al. (2023) · 老年心脏病学杂志:英文版 · doi:10.26599/1671-5411.2023.09.008 · Cited by 128
Teramoto, T., Kobayashi, M., Tasaki, H., Yagyu, H., Higashikata, T., Takagi, Y., Uno, K., Baccara‐Dinet, M. T., & Nohara, A. (2016) · Circulation Journal · doi:10.1253/circj.cj-16-0387 · Cited by 127
Vuorio, A. F., Watts, G. F., Schneider, W. J., Tsimikas, S., & Kovanen, P. T. (2019) · Journal of Internal Medicine · doi:10.1111/joim.12981 · Cited by 127
de Carvalho, L. S. F., Campos, A. M., & Sposito, A. C. (2018) · Diabetes Care · doi:10.2337/dc17-1464 · Cited by 121
Immune cell screening of a nanoparticle library improves atherosclerosis therapy
Tang, J., Baxter, S., Menon, A. A., Alaarg, A., Sánchez-Gaytán, B. L., Fay, F., Zhao, Y., Ouimet, M. I., Braza, M. S., Longo, V. A., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1609629113 · Cited by 130
Heparan sulfate proteoglycans present PCSK9 to the LDL receptor
Gustafsen, C., Olsen, D., Vilstrup, J., Lund, S., Reinhardt, A., Wellner, N., Larsen, T., Andersen, C. B. F., Weyer, K., Li, J., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00568-7 · Cited by 128
Toward an international consensus—Integrating lipoprotein apheresis and new lipid-lowering drugs
Stefanutti, C., Julius, U., Watts, G. F., Harada‐Shiba, M., Cossu, M., Schettler, V. J. J., Silvestro, G. D., Soran, H., van Lennep, J. E. R., Pisciotta, L., et al. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.04.114 · Cited by 122
Metadata
- Authors
- Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., Koren, M. J., Lepor, N. E., Lorenzato, C., Pordy, R., Chaudhari, U., & Kastelein, J. J. P.
- Affiliations
- University of Iowa (US)
- Centre Hospitalier Universitaire de Nantes (FR)
- Université de Lille (FR)
- Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" di Palermo (IT)
- Amsterdam UMC Location University of Amsterdam (NL)
- Oslo University Hospital (NO)
- University of the Witwatersrand (ZA)
- Jacksonville Center for Clinical Research (US)
- Westside Medical Associates of Los Angeles (US)
- Sanofi (France) (FR)
- Regeneron (United States) (US)
- Sanofi (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-04-16
- Volume
- 372
- Issue
- 16
- Pages
- 1489-1499
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2001328643
- Semantic Scholar
- 942bcfdc93b04ccb90a2d3e1df4c7950a45e92c2
- Cited by
- 2,296
- References
- 35
- Citations by year
- 2026: 67 · 2025: 103 · 2024: 150 · 2023: 141 · 2022: 134 · 2021: 159 · 2020: 165 · 2019: 226 · 2018: 251 · 2017: 339 · 2016: 369 · 2015: 183
- FWCI
- 383.69
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- VBN Forskningsportal (Aalborg Universitet) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- alirocumab, PCSK9 inhibition, LDL cholesterol lowering, statin therapy, major adverse cardiovascular events, cardiovascular risk reduction, monoclonal antibodies, injection site reactions, high-risk patients, lipid-lowering therapy
- MeSH terms
- Aged, Antibodies, Monoclonal, Anticholesteremic Agents, Cardiovascular Diseases, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Hypercholesterolemia, Cholesterol, LDL, Male, Middle Aged, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Intention to Treat Analysis, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.